💰 Grifter "Mad at the Internet" - a/k/a My Psychotherapy Sessions

  • 🏰 The Fediverse is up. If you know, you know.
  • Want to keep track of this thread?
    Accounts can bookmark posts, watch threads for updates, and jump back to where you stopped reading.
    Create account
He, himself and him are all the same interdimensional alien who tries his best to uplift humanity. Also to teach us the glory of fried chicken.
 
What would you call this type of Boomer?
 
I know it's preference and a rabbit hole but so much talk about mice you guys are going to think I'm insane for doing this. I've discovered my personal favorite mouse many years ago - Logitech G Pro Wireless. It's ultra light and fits my big ass hands perfectly. I have replaced the switches for left and right click 3 times now. Back twice, forward once. The battery once. I think I've had this thing for 6? years now.
 
Sneeds said:
What would you call this type of Boomer?
Fudd.mp4
Click to expand...
You can tell this fucking idiot boomer does not live anywhere near where he can experience the consequences of what he advocates for.

If Indians are speedrunning "most hated race" then boomers are speedrunning "most hated age bracket".
 
happy boxing day I know NULL going be happy with all the news next week for his show.
Forgot but time flies
TLDR: have to revive the hollywood thread in 2026 - 3year deal to 5year.
Feb 9. start of the strikes
edit/ps: after the merger talks with netflix & warner is a set deal beyound hostile take over next year.
1766776074543.png
Hollywood's major unions (SAG-AFTRA, DGA, WGA) traditionally use 3-year contracts, but as 2026 negotiations near, the studios (AMPTP) are proposing longer 5-year deals, offering significant health plan funding as a sweetener, a big shift from the typical cycle, especially after recent strikes, though formal proposals aren't out yet, reports The Hollywood Reporter and Deadline.
Key Points on the 5-Year Proposal:
A Major Shift: Industry norms have favored 3-year contracts since the 1940s, making a 5-year deal a significant change, notes MSN.
Studio Incentive: The Alliance of Motion Picture and Television Producers (AMPTP) is offering big cash injections for union health plans to entice agreement, say Deadline and Yahoo News UK.
Context: This comes after the crippling 2023 strikes, with the industry seeking stability, notes MSN.
Current Status: No formal proposals have been exchanged, but talks are anticipated as 2026 approaches, says The Hollywood Reporter.
Union Stance: Unions like SAG-AFTRA are reviewing the idea, with their final position dependent on member benefit, reports New York Post.
In Summary: The AMPTP is trying to shift Hollywood labor contracts to 5 years in upcoming 2026 talks, using major health fund contributions as leverage, a move that would alter decades of tradition and significantly impact union bargaining cycles, according to recent reports from Deadline and The Hollywood Reporter.
Click to expand...
...
To be clear, formal contract proposals haven’t been exchanged yet. Typically in entertainment labor negotiations, management and labor have some informal conversations in the months before bargaining begins to get a sense of where the other side is sitting.

The WGA, DGA and SAG-AFTRA will all return to the bargaining table with the AMPTP in 2026, with SAG-AFTRA kicking off the negotiations cycle on Feb. 9. The unions’ deals expire in the spring and summer of 2026.

Still, it’s notable that a major change to the industry’s typical bargaining schedule is even being contemplated. Since at least the 1940s, three-year deals have generally been the norm for entertainment unions, says Georgia State University associate professor Kate Fortmueller, who studies Hollywood labor.

“This would be a significant change to the cycles,” she adds. “I would also say this might make things more fraught; if you’re only doing this every five years, there’s a lot more weighing on every five years.”
Click to expand...
The AMPTP did not respond to a request for comment for this story.

A major unanswered question is how the unions would react to such a proposal if it materializes next year. The current three-year schedule comes with some perks for labor groups: With a more frequent schedule of sit-downs with employers, they can more quickly respond to industry trends and have more opportunities to modify the terms of their members’ work.
Click to expand...
That clip of dealmaking may be especially consequential in the generative AI era. The Writers Guild of America, Directors Guild of America and SAG-AFTRA first tackled the then-burgeoning technology in their 2023 negotiations, but in the years since then, AI tools — and the way industry companies use them — have rapidly evolved. Anticipating this, the three unions negotiated semi-annual sitdowns with employers for the purpose of discussing AI in their 2023 deals. AI is again expected to be a top issue for labor groups in 2026.

In other words, there might have to be significant sweeteners attached for major unions to seriously contemplate the idea. The WGA and SAG-AFTRA declined comment. The DGA did not respond to a request for comment
Click to expand...
Helming negotiations for the studios and streamers for the first time next year will be Gregory Hessinger, who took over from former AMPTP president Carol Lombardini earlier this year. Hessinger, a longtime employer-side labor lawyer, also has experience across the aisle: In the 2000s, he served as both the national executive director for the Screen Actors Guild and the American Federation of Television and Radio Artists, before they merged in 2012.

Could Hessinger’s AMPTP shake up the typical clip for union negotiations? That will be up to his labor partners. Says Fortmueller, “It seems like things are changing really rapidly and the face of the industry is changing in pretty radical ways. This would be a major change for labor. It’s a question of, do they see it to their advantage?”
Click to expand...
 
Null said:
niggercattle
Click to expand...
I bet you he wouldnt shoot a bixnood burglar in his home in fear of being labeled “raycist”
TyrasGuard said:
You can tell this fucking idiot boomer does not live anywhere near where he can experience the consequences of what he advocates for.

If Indians are speedrunning "most hated race" then boomers are speedrunning "most hated age bracket".
Click to expand...
Judging by the background I wouldn’t be surprised if he’s a Santa Fe New Mexico Shitlib
GoharMaria said:
Countless mass shootings, names 3
Click to expand...
He purposefully forgot to name Columbine, which happened during the Assault Weapons Ban
 
Last edited:
Nope alot of them are summaries & Vivek history.
Vivek Ramaswamy has faced accusations that one of his former companies, Axovant Sciences, was a "scam" or "pump-and-dump" scheme, though he has not been charged with any illegal activity. Critics claim he profited while other investors lost money when the company's key drug failed clinical trials.
Axovant Sciences Controversy
Company Strategy: Ramaswamy's biopharmaceutical company, Roivant Sciences, acquired an Alzheimer's drug (intepirdine) from GlaxoSmithKline for just $5 million, even though it had previously failed four clinical trials. The strategy was to revive shelved pharmaceuticals that large companies had underestimated.
IPO and Valuation: The drug was rebranded, and a new company, Axovant, was created for a record-breaking $2.2 billion initial public offering (IPO) in 2015, the largest biotech IPO at the time. The company's value briefly reached $3 billion on the hype surrounding the potential cure.
Profit and Failure: Around the peak valuation, Ramaswamy sold the bulk of his shares, making millions of dollars in personal profit. In 2017, the drug failed its final clinical trial, and Axovant's stock crashed, losing nearly all its value and costing thousands of other investors large sums of money. The company eventually dissolved in 2023.
Accusations: Critics, including political opponents and some investors, have described the operation as a "scam," a "fraud," or a "pump-and-dump" scheme, suggesting Ramaswamy had insider knowledge that the drug would fail.
Ramaswamy's Defense: Ramaswamy has not been found guilty of any illegal conduct. His defenders argue that he simply made a smart, legal business decision to sell his shares based on financial projections. He later acknowledged the drug's failure as a major setback.
Other Business Ventures and Accusations
Roivant Sciences: This was Ramaswamy's main biotech holding company, founded in 2014. Despite having multiple FDA-approved products eventually come from other subsidiaries, the company was never profitable during his tenure as CEO, consistently reporting massive net operating losses.
Strive Asset Management: Ramaswamy co-founded this "anti-woke" investment firm in 2022, which quickly reached $1 billion in assets under management by capitalizing on the political opposition to ESG (Environmental, Social, and Governance) investing. He has faced accusations of hypocrisy as his own investment portfolio included holdings in many "woke" companies he publicly criticized.
"Woke, Inc.": Ramaswamy authored a bestselling book titled Woke, Inc.: Inside Corporate America's Social Justice Scam, where he argues that corporate America uses social justice initiatives to distract from profits.
It is important to note that many of the accusations regarding his business practices have come from political opponents or critics and often lack legal findings of fraud or criminal activity. - ai
Click to expand...
1766778983265.png 1766779675887.png
google ai verified -
https://financhill.com/blog/investing/how-did-vivek-ramaswamy-make-his-money#- wiki summary
https://fortune.com/2023/08/24/vivek-ramaswamy-gop-debate-republican-net-worth/ - wiki summary
reddit, wiki
Vivek Ramaswamy's artful narrative, meticulously tailored for the GOP primary voter, weaves a tale of principled sacrifice and success. According to his version, he helmed the leadership of Roivant, a multi-billion-dollar American pharmaceutical company he founded, and gallantly relinquished his CEO role in 2021 due to his unwavering stance against ESG principles, despite facing opposition from his liberal workforce. While this narrative might seem appealing, it is akin to the endless "flip-flops" that have plagued his campaign—an elaborate work of fiction that unravels upon a modicum of scrutiny.

Let's start with the basics. Ramaswamy has funded his campaign through the sale of over $32 million in Roivant stock options in February of this year. This could lead one to believe that Roivant, based in Bermuda, is thriving and that Ramaswamy is a great entrepreneur. Except the company reported staggering losses of $1.2 billion in its financial report of March 2023. This isn't a one-time slump: In March 2022, when Ramaswamy was still Roivant's chairman and a major shareholder, the company reported an annual loss of $924.1 million.

Ramaswamy's defenders may argue that Roivant performed better during his tenure as CEO in 2021, but alas, the numbers tell a different story. The reality is that Roivant's finances were abysmal under Ramaswamy's watch. During his tenure in 2019, the company's net operating loss exceeded $530 million. By 2020, the losses had doubled to over $1 billion, accompanied by a 65 percent decline in revenue.
Click to expand...
These numbers raise a puzzling question: How can a company consistently bleeding billions trade at over $10 a share?

The answer might lie in Ramaswamy's implementation of Roivant's diversity, equity, and inclusion (DEI) initiative, called Roivant Social Ventures, during his CEO tenure. Launched in 2020 while Ramaswamy was still CEO, this initiative aimed to foster "DEI opportunities for future leaders in biopharma and biotech."

While Ramaswamy vocally opposes ESG principles, Roivant's major institutional investors—including Morgan Stanley, Viking Global, and BlackRock, the very firms he criticizes by name—are among its largest stakeholders, owning over 500 million shares. Ramaswamy himself holds more than 80 million shares, making him an essential partner of these major ESG funds.

In a deeply ironic twist, Ramaswamy's anti-"woke" campaign is being bankrolled by the profits reaped from the very policies he denounces.
Click to expand...
Yet this irony is not the worst of it. In 2015, there was another sordid affair involving Ramaswamy, over Axovant Sciences Alzheimer's drug. In June 2015, Ramaswamy appeared on CNBC to praise the Axovant IPO, which soared to over $30 a share based on expectations surrounding its Alzheimer's drug, Intepirdine. The drug was touted as a "breakthrough," yet upon closer examination, this development fell apart.
Click to expand...
Axovant had acquired the drug for $5 million in December 2014, six months before the IPO, after the majority of Phase 2 trials had "failed to meet their primary endpoints" in 2010. Ramaswamy devised a solution: His mother, Dr. Geetha Ramaswamy, conducted a new Phase 2 trial in 2015 involving "684 subjects." This trial conveniently claimed to demonstrate sufficient improvement to "support Phase 3" trials.

The aftermath was a triumphant $350 million IPO in 2015, followed by a drastic fall. By September 2017, the stock had plummeted 75 percent after Ramaswamy and his mother announced the Phase 3 trial's failure. Subsequent trials continued to disappoint, culminating in a 99 percent loss in value and a name change for the company.
Click to expand...
While investors suffered significant losses, Ramaswamy profited from a higher media profile, IPO payouts, and the sale of remaining Axovant assets in 2020.

Ramaswamy's latest scam appears to be his run for president. The 38-year-old presidential candidate appears to have no serious interest in leading the nation. In fact, according to people who know Ramaswamy, the goal of his campaign seems to be to block Florida Gov. Ron DeSantis' path to the nomination by running as a MAGA-adjacent candidate. Ramaswamy's deception has gone as far as hiring a writer to delete from his Wikipedia page his past ties to the Soros family and the creator of the mRNA vaccine.

Serving as Donald Trump's political fullback and hiding unflattering information from voters may not be a crime, but it is part of a disturbing pattern with Ramaswamy, which goes something like this: Generate media buzz, pull out right before the crash, and leave a rubble behind for others to clean up. In this case, the ones who will have to clean up his mess are Republican primary voters.

Thankfully, there are signs that conservatives may be catching on to Ramaswamy's ruse. A poll of Iowa Republican caucus goers taken immediately after last week's Fox News debate showed him dropping from third to fourth place, with his unfavorability ratings more than doubling. Clearly, Iowans didn't like what they saw. Who can blame them?
Click to expand...
 
waffle said:
It's the boomer-Fudd. One of the OG forms of boomer hate.
Click to expand...
“No one came for my guns during the assault weapons ban” Well yeah, you only own 22lr hunting rifles you retarded Fudd. God I fucking hate fudds
 
GungusDingaling said:
think there’s another dude that looks similar to these two as well that has some whacked out mad scientist bit. Pretty fun, I’d like to think they actually care about what they’re doing.
Click to expand...
That guy seems kind of genuine if a bit nuts.

There’s quite an untapped resource of black guys on YouTube who think they’re on the brink of inventing a free energy machine, but it’s not quite working yet so they start faking videos.
 
You must log in or register to reply here.
Back
Top Bottom